Prediction Model for Lateral Lymph Node Metastasis
Radiomics-based Prediction Model for Lateral Lymph Node Metastasis in Rectal Cancer
1 other identifier
observational
200
1 country
1
Brief Summary
Mid to low-lying rectal cancer patient with enlarged lateral lymph node befor treatment and receiving lateral lymph node dissection would be enrolled. Radiomics parameters of lateral lymph nodes would be extracted by expert software. Then a part of the nodes would be used as the training set to build the prediction model, and the another part nodes would be used as the validation set.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 13, 2020
CompletedFirst Posted
Study publicly available on registry
November 19, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedNovember 19, 2020
November 1, 2020
1.5 years
November 13, 2020
November 18, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
metastasis rate of lateral lymph node
2020.1-2022.12.31
Study Arms (2)
Trainning group
70% of the whole participants would be randomly divided into the training group to build the predicition model.
validation group
30% of the whole participant would be divided into the validation group to validate the model
Interventions
All participted would receive lateral lymph node dissection for rectal cancer.
Eligibility Criteria
patients with rectal cancer.
You may qualify if:
- middle to low-lying rectal adenocarcinoma patients with enlarged lateral lymph node ≥5mm for short diameter in CT and/or MRI
You may not qualify if:
- other kind of rectal tumor including neuroendocrine and malignant.
- high location rectal cancer.
- recurrent rectal cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guoxue Road 37#,West China Hospital
Chengdu, Sichuan, 610041, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
November 13, 2020
First Posted
November 19, 2020
Study Start
January 1, 2020
Primary Completion
June 30, 2021
Study Completion
December 31, 2022
Last Updated
November 19, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share
individual participant data (IPD) would not be available to other researchers.